Abstract
Introduction
Around 30% of individuals with schizophrenia will remain symptomatic and significantly impaired despite standard antipsychotic treatment and are considered to have treatmentresistant schizophrenia 1 . Treatment-resistance is usually defined as a failure to respond to two antipsychotic trials of sufficient dose and duration and is one of the most disabling forms of illness, and thus presents a major clinical challenge 2 . It is as yet unclear whether treatmentresistance is better conceptualised as a form of illness at the severe end of a spectrum, or as a more biologically homogeneous subgroup of those with schizophrenia, although recent evidence has supported the latter hypothesis 3 . Clozapine is the only medication with proven effectiveness for patients with treatment-resistant schizophrenia 4 . Nonetheless, substantial delays in receiving clozapine treatment are commonplace 5 , and these delays are associated with poorer outcomes 6 . Ensuring the right patients have timely access to clozapine is an important therapeutic goal in the management of people with schizophrenia 7 .
Although previous studies have identified clinical indicators of poor outcome in general, there have been relatively few studies investigating risk factors for treatment-resistance specifically.
The research that has been undertaken indicates that an early age of onset of psychosis, male sex, a longer duration of untreated psychosis, and poor premorbid functioning may be associated with treatment-resistance [8] [9] [10] . Although one study reported an enrichment of schizophrenia PRS in clozapine-treated patients 10 , this has not been replicated in larger subsequent studies 11, 12 . Other studies have reported an increased burden of genome-wide rare copy number duplications in treatment-resistant patients 12 , and an excess of rare disruptive variants in gene targets of antipsychotics 13 , although both of these studies are yet to be independently replicated. The identification of reliable factors could serve to alert clinicians and help predict those at greater risk of developing treatment-resistance when they first present with psychosis. This study aims to gain insights and identify factors measurable at illness onset that could be used predict treatment-resistant psychosis (TRP).
Methods

Sample characteristics
Study individuals were from the CardiffCOGS (COGnition in Schizophrenia, n=1070) sample, which has been previously described 14, 15 and additional details are provided in Supplementary
Methods. CardiffCOGS is a sample of patients with clinically diagnosed schizophrenia or related psychotic disorders recruited from community, in-patient and voluntary sector mental health services in the UK. Study individuals completed a comprehensive clinical interview based on the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) instrument, donated a blood sample for genetic analysis, and consented for access to their clinical case notes. The SCAN interview and clinical case notes were used to arrive at DSM-IV and ICD-10 lifetime diagnoses and to complete OPCRIT ratings. All study individuals had a diagnosis of schizophrenia or related psychotic disorder (detailed in Supplementary Table 1) . We included individuals with related psychotic disorders in addition to those with schizophrenia given that the study focuses on prediction at first presentation and diagnosis can be uncertain at this time. Thus, we refer to all samples as either TRP or non-TRP (whether the diagnosis is schizophrenia or a related psychotic disorder) and we undertake sensitivity analyses for all results to examine whether effects are consistent when restricted to those with narrowly defined schizophrenia. The sample shows a degree of enrichment for TRP as a result of targeted recruitment from clozapine clinics (52.4%
compared to a TRP prevalence of ~30% 
Outcome variable
Study individuals were diagnosed with TRP if they had either been rated negatively for OPCRIT item 89 'psychotic symptoms respond to neuroleptics' or had received clozapine treatment.
Individuals were diagnosed with non-TRP if they were rated positively for OPCRIT item 89 and had not received clozapine. OPCRIT item 89 was rated globally over the total period of illness based on interview and clinical notes data and scored positively if the illness appeared to respond to any type of antipsychotic or if relapse occurred when medication was stopped.
Individuals were excluded from the analyses (n=82) if (i) despite failure to respond to antipsychotics, they had not yet received two adequate antipsychotic trials at time of data collection or (ii) there was insufficient information to determine antipsychotic response.
Demographic, premorbid and illness onset clinical factors
To investigate characteristics that could at illness onset prospectively indicate a higher risk of TRP, we investigated variables related to demographics and family background, premorbid factors, and characteristics related to illness onset. These variables were derived from self-report at interview, clinical case notes and OPCRIT ratings. Full definitions of these variables are given in Supplementary Table 2 
Lifetime characteristics
In a secondary analysis, we investigated differences in post-onset symptom and outcome measures between individuals with TRP and non-TRP. These variables included demographics, lifetime clinical characteristics, clinical symptoms, and substance use (full details in Supplementary Table 3) .
Genetic liability for schizophrenia
Genotyping and quality control
The CardiffCOGS sample was genotyped on either the Illumina HumanOmniExpressExome-8 or the Illumina HumanOmniExpress-12 array as previously described 15 . After standard QC procedures, imputation was performed using IMPUTE2 16 
Copy number variation (CNVs)
The identification and quality control of CNVs in the CardiffCOGS sample has been previously described 19 and detailed in Supplementary Methods. To compare the enrichment of rare, pathogenic CNVs in TRP with non-TRP, we analysed the presence of an intellectual disability associated (ID) CNV 20 , the presence of a CNV previously associated with schizophrenia 19 , and the presence of any chromosomal deletions and duplications spanning 500kb or 1Mb in length.
Analysis
We conducted descriptive analyses to compare lifetime illness-related symptoms and outcome and an unbiased variable selection to control for different variable types. To derive an importance value for each variable, conditional permutation was used to control for any correlated variables. This permuted importance value represents the decrease in classification accuracy after randomly permuting the values of that variable over all trees. The accuracy of the conditional inference forest model was derived using the R 'caret' package 24 . The primary forest model could only be conducted in individuals with no missing data for the 21 variables analysed (n=337), and so we repeated the analyses in the remaining sample (up to n=733) for the five variables with the highest importance from the primary analysis. In order to make a direct comparison between the logistic regression and conditional inference forest models, we conducted a multivariate logistic regression in the 337 individuals with complete data. Rates of missing data for each variable are detailed in Supplementary Table 2 . The differences between individuals with and without missing data was assessed via logistic regression and detailed in Supplementary Table 4 ; there was no difference in sex, age at interview or method of recruitment but the participants with no missing data were less likely to have TRP (OR = 0.65, 95% CI = 0.50-0.84, p = 0.001).
To test the relationship between common variant genetic liability for schizophrenia on TRP, we regressed a model for each polygenic risk score created from various training p-value thresholds against a base model including the first five principal components and any additional principal components from the first 20 that were associated (p < 0.05) with TRP. To assess the proportion of variance explained we computed R 2 on the liability scale 25 , based on a TRP lifetime prevalence of 30% in schizophrenia, to account for ascertainment bias. The association of CNVs with TRP was tested via Firth's logistic regression 26 .
As this sample includes those with schizophrenia and related psychotic disorders, all analyses were replicated restricting the sample to those with a schizophrenia or schizoaffective disorder, depressed type diagnosis.
Results
A total 561 (52.4%) of the individuals included in the study were diagnosed with TRP and 509 (47.6%) with non-TRP. Due to our sampling methodology for this genetic study the vast majority of the participants (96.9%) were of White European ethnicity, and a total of 662 (61.9%) were male. Study individuals with TRP had a younger age at interview compared to those with non-TRP (OR = 0.98, 95% CI = 0.97-0.99, p = 6.48x10 -4 ) and were more likely to have been recruited from secondary mental care services (OR = 2.32, 95% CI = 1.76-3.04, p = 1.52 x10 -9 ). As potential confounders of no experimental interest both of these factors were included as covariates in subsequent regression analyses.
Lifetime characteristics
In a descriptive comparison of post-onset symptom and outcome measures, we found that individuals with TRP were more severely impaired than those with non-TRP across a range of measures (Supplementary Table 5 Table 6 ).
Demographic, premorbid and illness onset clinical factors
Univariate logistic regression
The association of demographic, premorbid and illness onset clinical factors with TRP are listed in Table 1 . Univariate analyses in the total sample (up to n=1070) found significant associations with TRP for an earlier age of onset of psychosis (OR = 0.94, 95% CI = 0.92-0.96, p = 7.79x10 -13 ) and poor premorbid social adjustment (OR = 1.64, 95% CI = 1.26-2.13, p = 2.41x10 -4 ). Lower premorbid IQ, poor premorbid work adjustment, and cannabis use in the year prior to illness onset were associated with TRP at p < 0.05 but did not survive correction for multiple testing.
Multivariate logistic regression
Clinical factors associated at p < 0.1 with TRP from the univariate analysis were included in a multivariate logistic regression ( Table 7) .
Conditional inference forest model
A conditional inference forest model was fitted to predict TRP based on 4000 trees using all 21
clinical factors previously described for 337 individuals with no missing data. The accuracy of the predictive model in this training dataset was 0.59. Using conditional permutation for importance factors (which represents the decrease in classification accuracy if the values of that variable are randomly permuted), we found that a younger age of onset of psychosis was the most important factor in the prediction of TRP, followed by poor premorbid social adjustment, family history of schizophrenia, lower premorbid IQ and poor premorbid work adjustment (Figure 1 ).
These findings were consistent in a model restricted to individuals with a diagnosis of schizophrenia (Supplementary Figure 2) . The importance of these top five variables was [ Figure 1 approximately here ]
Genetic liability for schizophrenia
Schizophrenia polygenic risk score (PRS)
Although individuals with TRP had a higher schizophrenia PRS on average across the p-value thresholds from the discovery cohort, this difference was only associated at a single threshold of P < 0.001 ( Table 2 ; R 2 = 0.011, OR = 1.20, 95% CI = 1.03-1.39, p = 0.016). These findings were consistent in analyses restricted to those with schizophrenia or schizoaffective depression (Supplementary Table 9 ). This study had 80% power to detect an association at p < 0.05, if the correlation between genetic effects on schizophrenia and TRP was 49% 27 .
Copy number variation (CNVs)
We found that there was no difference in the burden of rare, pathogenic CNVs previously associated with schizophrenia or intellectual disability in individuals with TRP compared to those with non-TRP ( Table 2) . Furthermore, we found no enrichment of 500kb or 1Mb deletions or duplications in individuals with TRP. These findings were consistent in analyses restricted to those with schizophrenia or schizoaffective depression (Supplementary Table 10 ). Our sample size had 80% power to detect an OR > 1.7 for a burden of CNVs with a frequency of 2.5% 28 at a significance level of p < 0.05 29 .
As genetic liability for schizophrenia (CNVs or PRS) was not associated with TRP, they were not combined in multivariate analyses with clinical factors.
Post hoc analyses related to age of onset of psychosis
Given the significant association of age of onset of psychosis with TRP, we conducted additional Age of onset of psychosis alone explained 7.3% of the variance (Nagelkerke R 2 ) of TRP, and had an area under the curve of 0.65. Figure 2 displays the relationship between age of onset and the proportion with TRP in our sample (data used given in Supplementary Table 11 Table 12 ).
We investigated whether the relationship between age of onset of psychosis and TRP could be explained by genetic liability to schizophrenia indicated by PRS and found that schizophrenia [ Figure 2 approximately here ]
Discussion
In this study we used regression and machine-learning analyses to determine whether genetic liability for schizophrenia and/or clinical characteristics measurable at illness onset can prospectively indicate a higher risk of TRP. We found age of onset of psychosis to be a significant and important clinical indicator in TRP. In addition, we found evidence across models that poor premorbid social functioning and lower premorbid IQ increased the risk of TRP. Genetic liability for schizophrenia indicated by polygenic risk scores and rare, pathogenic CNVs were not associated with TRP and did not explain the relationship with age of onset of psychosis.
Main findings
Age of onset of psychosis, defined as the age at which treatment was first sought or when symptoms first caused significant impairment (if earlier), was the most important indicator of TRP in this study; it was significant in univariate and multivariate regression analyses (OR = 0.95, 95% CI = 0.92-0.97) and had the highest importance value from conditional inference forest model. These findings were consistent in analyses restricting the sample to individuals with a schizophrenia diagnosis and were not influenced by clozapine-prescribing practice. An early age of onset of psychosis has been previously identified in several pervious studies as a predictor of TRP 8, 9, 12 . This study provides evidence that the increased risk for TRP is not restricted to those with a very early onset as suggested by previous studies 30, 31 but rather the risk of TRP continued to reduce throughout adulthood; the positive predictive value for treatment response to standard antipsychotics increased from 0.51 for individuals with an age of onset below 16 to 0.92 for those with an age of onset over 41 years of age. Given the continued reduction in the risk of TRP throughout adulthood, it seems unlikely that the relationship is explained by differences in provision of health services or related factors across different age groups.
Nonetheless, these findings do suggest the importance of engagement and proactive management of patients with an early age of onset of psychosis.
In this study we also found evidence for the role of premorbid factors in TRP. Poor premorbid In this study we did not find evidence of an association between TRP and several established risk factors for schizophrenia such as male sex, childhood abuse, duration of untreated psychosis, family history of psychosis, or urbanicity. A lack of association with these variables has also been reported in other studies of TRP 8, 12 , and provides support against a psychosis spectrum theory, under which you would expect to find increased rates of risk factors for schizophrenia in TRP.
However, in the case of early adversity, a previous study reported a cumulative effect of lifetime adversity in TRP 34 , suggesting that although we did not find an independent association with childhood abuse, it is possible it could be contributing to TRP in a cumulative manner.
We found no evidence for the association of genetic liability for schizophrenia indicated by PRS or rare, pathogenic CNVs with TRP. These findings are consistent with other studies investigating the association of schizophrenia PRS with TRP [10] [11] [12] , suggesting that genetic liability to TRP is not strongly influenced by liability to schizophrenia, beyond of course the requirement to have schizophrenia. However, larger samples are required to provide definitive answers in this regard. Within the power limitations of the study design, our findings add support to other evidence 3 suggesting that treatment-resistance may not be best conceptualised as a form of illness at the severe end of a psychosis spectrum, in which case you would expect a higher genetic loading of generic schizophrenia-associated SNPs in TRP patients. The use of PRS in the personalised prediction of TRP may be better informed by more specific training sets, for example from genetic studies investigating TRP directly, as opposed to PRS derived from those with a broad schizophrenia diagnosis.
Schizophrenia PRS was weakly associated with age of onset of psychosis in this study. However, the relationship between TRP and age of onset of psychosis in this study was not confounded or explained by differences in genetic liability to schizophrenia, suggesting that genetic factors influencing the age of onset of psychosis are distinct from those that increase liability for the disorder and may have particular relevance to treatment-resistance.
Lifetime characteristics
In a descriptive comparison of post-onset symptom and outcome measures, we found that individuals with TRP were more severely impaired than those with non-TRP; they were significantly more likely to have a continuous course of disorder, poorer cognitive functioning at the time of the interview, a higher number of psychiatric inpatient admissions, a lower GAS score, were more likely to deteriorate from their premorbid level of functioning, more likely to have been detained under the Mental Health Act, and have more severe positive and negative symptoms. Many of these findings have been previously documented 2 , but few studies have looked at so many variables in a single cohort of this size. These findings reinforce the importance of efforts to identify early indicators of TRP and thus improve the ability of clinicians to identify and appropriately treat those with an increased risk of TRP.
Strengths and limitations
A strength of the study is the use of a single large schizophrenia and related psychotic disorders sample with detailed clinical phenotypes derived from both interview and clinical case notes.
Consequently, the outcome variable of TRP is of a high quality, including confirmed treatmentresponders as controls, which is not the case for many studies in this field. We did not have objective evidence (such as medication serum levels) to confirm treatment resistance but our TRP definition takes non-adherence into account given it relies upon either clinician diagnosis of treatment resistance to prescribe clozapine or was based on ratings from interview and clinical note review taking into account reported non-adherence. A further strength is the use of both regression and machine learning approaches. Machine learning models are increasingly being applied in prediction models for disease and to inform the personalised prevention of disease 35 .
The primary limitation of this study is the use of retrospective reports for the premorbid and illness onset variables although the use of contemporaneous clinical records will have increased the reliability of the key clinical variables such as age of onset of psychosis. The study sample is enriched for individuals with TRP (52% vs. estimated 30% prevalence) as a result of targeted recruitment from clozapine clinics. Recruitment strategy was controlled for in regression analyses, which did not alter the results, and all predictive values were corrected for prevalence and thus we do not believe that this enrichment biases the results of the study. We found minor but consistent levels of missing data across clinical variables, which significantly reduced the sample size in multivariate analyses. However, we were able to replicate our findings in these excluded individuals for smaller subsets of associated variables. We were not able to incorporate some factors into the present study that may have impacted the likelihood of treatment-resistance such as type of individual antipsychotics prescribed and other treatments received. Lastly, like many genetic studies, our analyses primarily consisted of individuals of White European ethnicity and thus further studies are required to establish the generalisability of these findings to all TRP patients.
Future research and clinical implications
The results in this study indicate that genetic studies investigating TRP directly, rather than a broad schizophrenia diagnosis, will be needed to gain insights into the nature of treatment- Table 1 : Association of demographic, premorbid and illness onset clinical factors with treatment-resistant schizophrenia (TRP). Columns represent clinical variables, TRP, non-TRP (reference group), odds ratio (OR), 95% confidence intervals (CI) and P-value from univariate logistic regression adjusted for age at interview and method of recruitment, and adjusted multivariate logistic regression. For binary variables, numbers (N) and percentages (%) are provided, and for continuous variables, mean and standard deviation (sd) are provided. P-values in bold were significant at P < 0.05. Table 2 : Association of genetic liability for schizophrenia with TRP. Columns for schizophrenia PRS represent the p-value threshold used in discovery cohort to derive scores, odds ratio (OR) and 95% confidence intervals, R 2 calculated on the liability scale 25 , area under the curve (AUC), standard error (SE), and P-value of association of each score of with TRP. Columns for CNV analysis represent CNVs assessed, frequencies of each CNV in non-TRP (reference group), TRP, odds ratio (OR), 95% confidence intervals (CI) and P-value from Firth's logistic regression. Green dots represent proportion of sample with TRP for each age of onset. Grey area represents 95% confidence intervals. Data used to produce plot is provided in Supplementary  Table 11 ; the minimum number of per group was 23 individuals, and the mean average number per group was 40 individuals.
